MENU
OCT 7 - 8 2020 Opens: 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Cancer Research & Oncology 2020

LabRoots and the Cancer Research and Oncology Planning Committee are pleased to announce the 8th Annual Cancer Research and Oncology Virtual Event! This two day event will take place on October 7th and 8th, 2020 and will focus on advancements in prevention, diagnosis and treatment of different cancer types.

Cancer research has made major advancements in diagnosis, treatments, and the basic understanding of the disease itself. Each year we see progress in immunotherapy, treatments involving nanotechnology, advances in targeted and personalized therapeutics and drug development, and a decrease in mortality rates due to a strong focus on learning more about the origination of the disease.

This year's event will include the following tracks:
  • The Role of Evolution in Drug and Radiation Resistance of Cancer
  •  The latest in Immunotherapy and Other Novel Cancer Therapeutics
  •  Health Disparities: How Cancer Impacts the Underrepresented and Underserved
  •  Molecular/Genetic Guidance Versus Standard of Care
  •  New Methods to Understand Cancer Biology

Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event.  The webinars will be available for unlimited on-demand viewing.  This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.

Like the 2019 conference, this event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.



Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2020 Cancer Research and Oncology Virtual Event. Submission is free. Submit your abstract here.

Continuing Education
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 35 credits.

Use #LRcancer to follow the conversation!


Speakers
  • Associate Professor, Vice Chair for Diversity, Equity and Inclusion, Department of Population Health Sciences, Duke University School of Medicine, Associate Research Professor, Duke Global
  • Gilead Sciences, Foster City, CA Jan., 2011 - current Associate Scientist I (2011-2013), Biologics and Target Biology Associate Scientist II (2014-2015), Biomarker / Biology Core Support
  • Head of Portfolio Management and Product Development, Genome Engineering & Modulation
  • Senior Scientist, Digital PCR Assay Development, QIAGEN GmbH
  • Senior Staff Scientist, Division of Cellular Signaling, Research Institute, National Cancer Center
  • Professor, Dept. of Biomedical and Biological Sciences, JLC Biomedical Biotechnology Research Institute, North Carolina Central University
  • Senior Research Investigator II, Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, NJ, USA
  • Assistant Professor, Division of Medical Oncology, Huntsman Cancer Institute
  • Sr. Director, Development at Biodesix, Inc.
  • Medical Director, AdventHealth Global Robotics Institute, Medical Director, AdventHealth Cancer Institute Urologic Oncology Program, Professor of Urology, University of Central Florida
  • Deputy Director, Duke Cancer Institute, Professor of Medicine, Professor of Pharmacology and Cancer Biology, Professor of Family Medicine and Community Health, Duke University Medical Center
  • Director, Robotic Surgery, Providence St. Joseph Health Care System and Swedish Medical Center
  • Professor of Cancer Immunotherapy, Nottingham Trent University, United Kingdom
  • Director, R&D, QIAGEN
  • Head of Antibody Development
  • Assistant Attending Physician-Scientist, Memorial Sloan Kettering Cancer Center
  • Associate Director, PreAnalytiX R&D, QIAGEN

Show Resources
Agenda
Scheduled
  • Keynote Presentation: RNA Splicing and Ancestry-related Molecular Targets in Precision Oncology and Cancer Disparities
    OCT 07, 2020
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: RNA Splicing and Ancestry-related Molecular Targets in Precision Oncology and Cancer Disparities
    Steven R. Patierno, PhD
    Deputy Director, Duke Cancer Institute, Professor of Medicine, Professor of Pharmacology and Cancer Biology, Professor of Family Medicine and Community Health, Duke University Medical Center
  • Blood-based detection of EGFR and KRAS mutations for NSCLC patients using multiplexed droplet digital PCR
    OCT 07, 2020 9:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Blood-based detection of EGFR and KRAS mutations for NSCLC patients using multiplexed droplet digital PCR
    Hestia Mellert, PhD
    Sr. Director, Development at Biodesix, Inc.
    Sponsored By: Bio-Rad Laboratories
  • Keynote Presentation: Principles of Effective Method Development in Pathobiology Research.
    OCT 07, 2020 9:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Keynote Presentation: Principles of Effective Method Development in Pathobiology Research.
    Vivian Barry, MS
    Gilead Sciences, Foster City, CA Jan., 2011 - current Associate Scientist I (2011-2013), Biologics and Target Biology Associate Scientist II (2014-2015), Biomarker / Biology Core Support
    Sponsored By: Roche Diagnostics
  • Immune correlates of TP53 mutational status in acute myeloid leukemia
    OCT 07, 2020 1:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Immune correlates of TP53 mutational status in acute myeloid leukemia
    Dr. Sergio Rutella
    Professor of Cancer Immunotherapy, Nottingham Trent University, United Kingdom
    Sponsored By: NanoString Technologies
The following webinars will be readily on-demand when the event starts
  • Immunotherapy in Prostate and Renal Cell Carcinoma: Panoply of Futuristic Therapies
    Immunotherapy in Prostate and Renal Cell Carcinoma: Panoply of Futuristic Therapies
    Benjamin Maughan, MD, PharmD
    Assistant Professor, Division of Medical Oncology, Huntsman Cancer Institute
    Continuing Education: Florida CE | P.A.C.E. CE
  • Oncogene additivity in the PI3K pathway in cancer
    Oncogene additivity in the PI3K pathway in cancer
    Neil Vasan, MD, PhD
    Assistant Attending Physician-Scientist, Memorial Sloan Kettering Cancer Center
    Continuing Education: Florida CE | P.A.C.E. CE
  • The biology of cancer disparities: an innate immunity story
    The biology of cancer disparities: an innate immunity story
    K. Sean Kimbro, PhD
    Professor, Dept. of Biomedical and Biological Sciences, JLC Biomedical Biotechnology Research Institute, North Carolina Central University
  • Transcriptome analysis of breast cancer clinical specimens with long-read sequencer
    Transcriptome analysis of breast cancer clinical specimens with long-read sequencer
    Masahito Kawazu, MD
    Senior Staff Scientist, Division of Cellular Signaling, Research Institute, National Cancer Center
  • We Don't Care What You Know Until You Show Us That You Care': Characterizing Access to Healthcare among Black, Hispanic and White Cancer Survivors
    We Don't Care What You Know Until You Show Us That You Care': Characterizing Access to Healthcare among Black, Hispanic and White Cancer Survivors
    Tomi Akinyemiju, PhD, MS
    Associate Professor, Vice Chair for Diversity, Equity and Inclusion, Department of Population Health Sciences, Duke University School of Medicine, Associate Research Professor, Duke Global
    Continuing Education: Florida CE | P.A.C.E. CE
  • High-throughput biomarker profiling in immuno-oncology research & development
    OCT 08, 2020 6:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    High-throughput biomarker profiling in immuno-oncology research & development
    Jenny Koenitzer, PhD
    Senior Research Investigator II, Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, NJ, USA
    Sponsored By: MilliporeSigma
  • Reducing biological variance in tumor-antigen expression to standardize potency testing for immunotherapies
    OCT 08, 2020 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Reducing biological variance in tumor-antigen expression to standardize potency testing for immunotherapies
    Benjamin Borgo, PhD
    Head of Portfolio Management and Product Development, Genome Engineering & Modulation
    Sponsored By: MilliporeSigma
  • ZooMAb® Antibodies- a Novel Recombinant Antibody Technology
    OCT 08, 2020 9:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    ZooMAb® Antibodies- a Novel Recombinant Antibody Technology
    Wayne Speckmann, PhD
    Head of Antibody Development
    Sponsored By: MilliporeSigma
  • Nucleic acid preparation - DNA, RNA and retrieving both from the same FFPE sample
    OCT 08, 2020 10:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Nucleic acid preparation - DNA, RNA and retrieving both from the same FFPE sample
    Martin Schlumpberger, PhD
    Associate Director, Scientific Applications, Sample Technologies Development, Qiagen GmbH
    Sponsored By: QIAGEN
  • Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system
    OCT 08, 2020 12:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system
    Dr. Özlem Karalay
    Senior Scientist, Digital PCR Assay Development, QIAGEN GmbH
    Sponsored By: QIAGEN
  • Multimodal analysis of circulating cell-free RNA (ccfRNA), cell-free DNA (ccfDNA), genomic DNA (gDNA) and CTCs from blood samples in cancer research
    OCT 08, 2020 1:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Multimodal analysis of circulating cell-free RNA (ccfRNA), cell-free DNA (ccfDNA), genomic DNA (gDNA) and CTCs from blood samples in cancer research
    Thorsten Voss, PhD
    Associate Director, PreAnalytiX R&D, QIAGEN
    Sponsored By: QIAGEN
  • The latest in Immunotherapy and Other Novel Cancer Therapeutics
  • Immunotherapy in Prostate and Renal Cell Carcinoma: Panoply of Futuristic Therapies
    Immunotherapy in Prostate and Renal Cell Carcinoma: Panoply of Futuristic Therapies
    Benjamin Maughan, MD, PharmD
    Assistant Professor, Division of Medical Oncology, Huntsman Cancer Institute
    Continuing Education: Florida CE | P.A.C.E. CE
  • Immune correlates of TP53 mutational status in acute myeloid leukemia
    OCT 07, 2020 1:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Immune correlates of TP53 mutational status in acute myeloid leukemia
    Dr. Sergio Rutella
    Professor of Cancer Immunotherapy, Nottingham Trent University, United Kingdom
    Sponsored By: NanoString Technologies
  • Health Disparities: How Cancer Impacts the Underrepresented and Underserved
  • The biology of cancer disparities: an innate immunity story
    The biology of cancer disparities: an innate immunity story
    K. Sean Kimbro, PhD
    Professor, Dept. of Biomedical and Biological Sciences, JLC Biomedical Biotechnology Research Institute, North Carolina Central University
  • New Methods to Understand Cancer Biology
  • Nucleic acid preparation - DNA, RNA and retrieving both from the same FFPE sample
    OCT 08, 2020 10:30 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Nucleic acid preparation - DNA, RNA and retrieving both from the same FFPE sample
    Martin Schlumpberger, PhD
    Associate Director, Scientific Applications, Sample Technologies Development, Qiagen GmbH
    Sponsored By: QIAGEN
  • Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system
    OCT 08, 2020 12:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Multiplex detection of oncogenic mutations using LNA-based assays on the QIAcuity digital PCR system
    Dr. Özlem Karalay
    Senior Scientist, Digital PCR Assay Development, QIAGEN GmbH
    Sponsored By: QIAGEN
  • Multimodal analysis of circulating cell-free RNA (ccfRNA), cell-free DNA (ccfDNA), genomic DNA (gDNA) and CTCs from blood samples in cancer research
    OCT 08, 2020 1:30 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Multimodal analysis of circulating cell-free RNA (ccfRNA), cell-free DNA (ccfDNA), genomic DNA (gDNA) and CTCs from blood samples in cancer research
    Thorsten Voss, PhD
    Associate Director, PreAnalytiX R&D, QIAGEN
    Sponsored By: QIAGEN
Posters

POSTER SUBMISSION GUIDELINES

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.


SUBMIT YOUR ABSTRACT

Enter the following information to this Submission Form:

  • Poster Title
  • Your Name
  • Your Institution
  • Your Email
  • Abstract describing the poster


All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

Questions? Email Posters@LabRoots.com

LabRoots Policy

Speakers

  • Tomi Akinyemiju, PhD, MS
    Associate Professor, Vice Chair for Diversity, Equity and Inclusion, Department of Population Health Sciences, Duke University School of Medicine, Associate Research Professor, Duke Global
    Biography

      Dr. Akinyemiju is an Associate Professor of Epidemiology with expertise in cancer epidemiology, cancer biology, epidemiologic methods, and health disparities.  Her research interests include quantifying the impact of social (e.g. access to healthcare and structural racism) and biological factors (e.g. metabolic and inflammatory dysregulation) on racial disparities in cancer risk, tumor aggressiveness, quality of treatment and survival. This line of inquiry has resulted in over 100 publications till date. Dr. Akinyemiju is the PI of an NIH funded study examining the role of metabolic dysregulation and associated epigenetic changes in risk of aggressive, hormone-receptor negative breast cancer in women of African descent, and an R01 characterizing racial differences in various healthcare access dimensions, and how these predict poor treatment utilization and lower survival among Black, Hispanic and White ovarian cancer patients. These ultimate goal of these studies is to provide novel, empirical and generalizable insights that can help identify and prioritize specific modifiable factors that can be targeted to reduce cancer disparities and improve care for all patients, findings that will likely be beneficial across a range of cancer types where racial disparities remain an intractable problem.

    • Vivian Barry, MS
      Gilead Sciences, Foster City, CA Jan., 2011 - current Associate Scientist I (2011-2013), Biologics and Target Biology Associate Scientist II (2014-2015), Biomarker / Biology Core Support
      Biography

        Vivian Barry is a Senior Scientist in the Pathobiology group at Gilead Sciences.  She began her career in molecular biology and immunology research areas at DNAX and Genentech.  She eventually ventured into histopathology research and became the manager of the immunohistochemistry team at Arresto Biosciences in 2008.  Vivian joined Gilead in 2011, with the acquisition of Arresto, and has been managing the IHC/Pathology group at Gilead since that time.  Over the years, she has focused on building the histopathology lab and has introduced various machinery and techniques to enhance the delivery of high quality IHC and CISH data.  Her team focuses on target validation in both human tissues and animal models, assists in determining mechanism of action of therapeutics and small molecules, and is involved in IND-enabling studies.  She collaborates with investigators across Gilead’s departments; these projects include virology, immunology, oncology, and fibrotic diseases.  Vivian received her Bachelor of Science and Master of Science degrees at the University of San Francisco, and has recently received her MBA from the Golden Gate University, San Francisco.

      • Benjamin Borgo, PhD
        Head of Portfolio Management and Product Development, Genome Engineering & Modulation
        Biography

          Ben currently leads a team of forward-thinking product and service managers within MilliporeSigma's Genome Engineering and Modulation franchise. His first exposure to CRISPR-based genome editing was as a graduate student where he attempted to engineer novel protein variants. This work inspired a passion for CRISPR technology which he has brought with him to his current role within a company that is laser-focused on developing and utilizing revolutionary genome editing technologies. Prior to joining Merck KGaA, he has worked in various commercial and technical roles at Berkeley Light Inc., Agilent Technologies, Nanopore Diagnostics, and several small start-up companies focused on software applications. Ben has a PhD in computational biology from Washington University in St. Louis.

        • Dr. Özlem Karalay
          Senior Scientist, Digital PCR Assay Development, QIAGEN GmbH
          Biography

            Dr. Özlem Karalay, Senior Scientist, Digital PCR Assay Development, QIAGEN GmbH Özlem Karalay studied Molecular Biology & Genetics at the Middle East Technical University, Turkey, and obtained her M.Sc. degree in Neuroscience from the MPI for Developmental Biology, Tübingen. She received her doctorate in Neuroscience from the Swiss Federal Institute of Technology (ETH), Zürich. She joined QIAGEN after completion of her postdoctoral research at the MPI for Biology of Ageing, Cologne, and since then has been involved in developing the digital PCR assay portfolio, including mutation detection and CNV assays.

          • Masahito Kawazu, MD
            Senior Staff Scientist, Division of Cellular Signaling, Research Institute, National Cancer Center
            Biography

              Masahito Kawazu began his medical research after studying medicine at the University of Tokyo and being trained as a hematologist. After earning a degree in research on transcription factors and conducting research on transcriptional regulators as a postdoctoral fellow, he joined  Department of Cellular Signaling, The University of Tokyo, in 2010 and started his research on genomic medicine. His research focuses on genomic abnormalities of cancer cells. He aims to find genomic abnormalities that drive the growth of cancer or that affect the immune environment of cancer. He performed a genome analysis of breast cancer and microsatellite instability-high colorectal cancer, and clarified the characteristics of their genomic abnormality. Recently, his team is trying to analyze the abnormal transcripts resulting from the structural variations (chromosomal rearrangement) of cancer genome using a long-read sequencer.

            • K. Sean Kimbro, PhD
              Professor, Dept. of Biomedical and Biological Sciences, JLC Biomedical Biotechnology Research Institute, North Carolina Central University
              Biography

                Dr. Kimbro is a biomedical scientist, educator, and community researcher. With a career-spanning nearly thirty years in a wide variety of institutions across this country, Dr. Kimbro has continued to pursue excellence in the classroom and at the bench. He currently serves as a Professor of Biological and Biomedical Science at North Carolina Central University (NCCU) where his research focus involves the innate immune response pathway in cancer development and risk in African American populations. He returned to full-time research after serving as the Director of the Julius L. Chambers Biomedical/Biotechnology Research Institute (Institute). Dr. Kimbro’s cancer disparities expertise is widely recognized as evidenced by serving as a peer-reviewer of grants for the National Institutes of Health and his multiple peer-reviewed publications in health disparities. Dr. Kimbro is passionate about developing the next generation of investigators and has consistently been regarded as a favorite among graduate and undergraduate students alike. He is deeply committed to his community and has exercised considerable leadership in the area of health disparities. Prior to joining NCCU, Dr. Kimbro served as the Program Director of the Georgia Center for Health Equality at the Emory University School of Medicine, Winship Cancer Institute, a NIH Center of Excellence (COE). In his role at the Institute, Sean was instrumental in managing a variety of programs and initiatives to identify and address health disparities, particularly in the African-American community. Dr. Kimbro holds a B.A. in Biology from Washington University in St. Louis and a Ph.D. in Biological Sciences, with an emphasis in Molecular and Microbiology from Indiana University. He completed post-doctoral positions at Harvard University Medical School and the National Institutes of Health, National Institute of Environmental Health Sciences at Research Triangle Park, North Carolina.

              • Jenny Koenitzer, PhD
                Senior Research Investigator II, Leads Discovery & Optimization, Bristol Myers Squibb, Princeton, NJ, USA
                Biography
                  Dr. Koenitzer is an immunobiologist in R&D at Bristol Myers Squibb in Princeton, NJ. During her time at BMS, she has focused on small molecule and biologics drug discovery in the immuno-oncology space.
                • Benjamin Maughan, MD, PharmD
                  Assistant Professor, Division of Medical Oncology, Huntsman Cancer Institute
                  Biography

                    Benjamin Maughan MD, PharmD is an Assistant Professor in the Division of Medical Oncology at Huntsman Cancer Institute specializing in genitourinary malignancies. Dr. Maughan completed his PharmD, cum laude, from Idaho State University in 2004, then completed an oncology pharmacy residency at Mountain States Tumor Institute in 2005. Dr. Maughan earned his MD, cum laude, from the University of Kentucky, College of Medicine in 2010. He finished his Internal Medicine residency training with the University of Utah in 2013 and subsequently completed his medical oncology fellowship at Johns Hopkins in 2016. He has been awarded the Huntsman Cancer Institute Translational Scholar Award in 2019, and was selected for the 2019 SWOG Young Investigator Training Course. Dr. Maughan has clinical and research interests in all genitourinary oncology, with a particular focus on the development of novel therapeutics and in identification of predictive biomarkers. During fellowship he studied predictive biomarkers in metastatic prostate cancer, specifically the role of truncated androgen receptors (AR-V7 expression) and loss of tumor suppressors (PTEN and Rb). More recently he is studying predictive biomarkers to immune therapy combinations in kidney, bladder and prostate cancers. He is exploring novel immune therapy combinations including checkpoint inhibitors combined with radiation therapy (radium-223), oncolytic viruses (MVA-brachyury) and targeted therapies (such as cabozantinib).

                  • Hestia Mellert, PhD
                    Sr. Director, Development at Biodesix, Inc.
                    Biography

                      Dr. Mellert is a Senior Director within the Biodesix development group.  She has a background in molecular cancer biology and experience leading teams in the development and commercialization of blood-based, and now respiratory based, diagnostic tests under CAP/CLIA and NYS CLEP.  Dr. Mellert has played a leading role in the launch and on-market support of the GeneStrat tests which uses ddPCR technology. Most recently she has contributed to the expanded use of this platform at Biodesix to support molecular testing for SARS-CoV-2 infection.  She continues to focus her efforts on bringing relevant and actionable genomic and proteomic information into the Clinical Laboratory to support pharmaceutical development programs and physicians. Dr. Mellert received her Ph.D from the University of Pennsylvania and post-doctoral training at the University of Colorado.  She has received several honors including the American Cancer Society Post-doctoral fellowship and inaugural Biodesix Invent Our Future award.

                    • Vipul Patel, MD
                      Medical Director, AdventHealth Global Robotics Institute, Medical Director, AdventHealth Cancer Institute Urologic Oncology Program, Professor of Urology, University of Central Florida
                      Biography

                        Vipul Patel, MD, FACS completed his medical school education at Baylor College of Medicine in Houston, TX.  He then completed his residency and fellowship training at the University of Miami in Florida.  Subsequently, Dr. Patel served as director of the Robotic Surgery Program at The Ohio State University in Columbus, Ohio, prior to joining Advent Health Celebration. Dr. Patel is board certified by the American Urological Association and is the medical director of the Global Robotics Institute at Advent Health Celebration and medical director of the Advent Health Cancer Institute Urologic Oncology Program.  He is a professor of Urology at the University of Central Florida College of Medicine in Orlando, Florida, and a clinical associate professor of Urology at Nova Southeastern University, also in Orlando. He serves as an honorary professor at the University of Milan, Korea University and Ricardo Palma University in Lima, Peru, and was recently made an honorary professor of the Russian Academy of Science. He is the founder of the International Prostate Cancer Foundation (IPCF) and a founding member of the Society of Robotic Surgery.  He is the editor emeritus of The Journal of Robotic Surgery and editor of the first-ever robotic urology textbook. He leads one of the world’s most experienced robotic surgery teams and travels around the world to educate physicians and care for patients. Dr. Patel is world-renowned for his contribution to the field of robotic surgery and prostate cancer. Dr Patel is the most experienced robotic surgeon in the world and has personally performed nearly 14,000 robotic prostatectomies for the treatment of prostate cancer. Dr. Patel has developed techniques in robotic surgery that have translated to improve patient care and outcomes. His innovations have helped to improve cancer treatment and return of early urinary continence and sexual function. His contributions have been recognized worldwide through publications, professorships and training courses. He has traveled the globe lecturing and teaching. He has educated thousands of surgeons in robotic surgical techniques. He has started robotic surgery programs or performed surgery throughout the United States and in countries, including India, China, England, Sweden, Belgium, Turkey, Australia and South Korea. He currently serves as president of the Florida Urologic Society and Past president and Managing Director of the Society of Robotic Surgery.

                      • Steven R. Patierno, PhD
                        Deputy Director, Duke Cancer Institute, Professor of Medicine, Professor of Pharmacology and Cancer Biology, Professor of Family Medicine and Community Health, Duke University Medical Center
                        Biography

                          Steven R. Patierno, PhD serves as Professor of Medicine, Professor of Pharmacology and Cancer Biology and Professor of Family Medicine and Community Health at the Duke University School Medicine, and as Deputy Director of the Duke Cancer Institute (DCI), one of the original eight NCI-designated Comprehensive Cancer Centers. He earned a Bachelor of Science in Pharmacy from the University of Connecticut, a PhD in molecular pharmacology from the Graduate School of Biomedical Science, University of Texas Health Science Center-MD Anderson Cancer Institute in Houston Texas, and conducted an NIH-awarded postdoctoral fellowship at the University of Southern California (USC) Norris Comprehensive Cancer Center in molecular oncology and carcinogenesis. He was the Vivian Gill Distinguished Professor of Oncology, and Professor of Pharmacology, Physiology and Urology at the GWU School of Medicine and Health Sciences, and served as Executive Director of The George Washington University Cancer Center for ten years prior to moving to Duke in 2012. Dr. Patierno’s basic science and translational research laboratory has been funded continuously by the NIH, NCI, Department of Defense and multiple foundations for over 25 years. He is internationally recognized for research on molecular carcinogenesis, molecular pharmacology and oncology, the genomics of cancer disparities and healthcare delivery research on patient navigation and evidence-based policy. Currently, his laboratory is focused on the molecular biology of cancer disparities including the development of biomarkers for high risk cancer and identification and development of novel molecularly targeted therapeutics.  He serves on many national committees for AACR, AACI, and ASCO, and as chair of numerous scientific and medical advisory boards.  He co-chaired the 2007, and keynoted the 2018 AACR-NCI Think Tanks on Cancer Disparities and help found the AACR Science of Cancer Disparities Annual Conference. Dr. Patierno received a Prostate Cancer Foundation 2018 Challenge Award, the AACR 2019 Distinguished Cancer Disparities Research Award, and has been recognized as a Distinguished Alumnus of the University of Texas MD Anderson Cancer Institute.  He has also been recognized by Duke University for his extensive work in Diversity and Inclusion and by numerous organizations for impactful community engagement.

                        • Dr. James Porter
                          Director, Robotic Surgery, Providence St. Joseph Health Care System and Swedish Medical Center
                          Biography

                            Dr. James Porter is Director of Robotic Surgery at Providence St. Joseph Health Care System and Swedish Medical Center in Seattle, Washington.  He is former Associate Professor of Urology and head of laparoscopy and robotics in the Department of Urology at the University of Washington Medical Center.  He performed the first laparoscopic radical prostatectomy in the Pacific Northwest on October, 2000.  His area of expertise is robotic assisted prostatectomy, and partial nephrectomy.   He developed the retroperitoneal approach for robotic renal surgery and pioneered retroperitoneal lymph node dissection for the treatment of testicular cancer.  He has been director of a fellowship in robotic and laparoscopic surgery for the last 18 years.  He is the most experienced laparoscopic and robotic surgeon in the Pacific Northwest and has performed over 4,000 robotic procedures.   He earned his undergraduate degree in biochemistry at Ohio State University.  He received his medical degree from the Medical College of Ohio and performed his urology residency at the University of Washington Medical Center.  He obtained advanced laparoscopic training in Heilbronn, Germany under the direction of Dr. Jens Rassweiler.

                          • Dr. Sergio Rutella
                            Professor of Cancer Immunotherapy, Nottingham Trent University, United Kingdom
                            Biography

                              Professor Rutella is a licensed haematologist and Professor of Cancer Immunotherapy at the John van Geest Cancer Research Centre. His academic career has been predicated on the bench-to-bedside-to-bench paradigm in Haematology. Over the last 25 years, Professor Rutella has been engaged in clinical and translational research focusing on immunotherapy approaches to improve the outcome of haematological malignancies, with an emphasis on antibody-based therapeutics and haematopoietic stem cell transplantation. At Nottingham Trent University, Professor Rutella’s research program focuses on visualising the state of cancer-immune interactions in individual patients and on biomarker discovery, with the aim to design rational immunotherapy approaches and to guide treatment choices.

                            • Martin Schlumpberger, PhD
                              Director, R&D, QIAGEN
                              Biography

                                Martin Schlumpberger is Director, Product Development at QIAGEN focusing on exosomes and circulating, cell-free nucleic acid isolation. Before his current role, he successfully led the development of various RNA isolation products at QIAGEN, including RNeasy FFPE, RNeasy Plus, AllPrep DNA/RNA, miRNeasy and QIAsymphony RNA kits. Prior to joining QIAGEN, Martin worked as a postdoctoral fellow at the Institute for Neurodegenerative Diseases at UCSF, USA. He holds a Ph.D. in chemistry, with a strong focus on molecular biology and yeast genetics, from the University of Stuttgart, Germany.

                              • Wayne Speckmann, PhD
                                Head of Antibody Development
                                Biography

                                  Dr. Wayne Speckmann has been working in R&D for over 20 years and is an expert in antibody development and immunoassays.

                                • Neil Vasan, MD, PhD
                                  Assistant Attending Physician-Scientist, Memorial Sloan Kettering Cancer Center
                                  Biography

                                    Neil Vasan is an Assistant Attending Physician on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. He is a physician-scientist working in the laboratory of Dr. Lewis Cantley (Weill Cornell Medical College) on oncogenic kinases and mechanisms of response to targeted therapies, with a focus on breast cancer. His work has been published in Nature and Science. He has received the NIH/NCI K08 Award, the Susan G. Komen Career Catalyst Research Award, the ASCO Young Investigator Award, and was named a 2020 AACR NextGen Star.

                                  • Thorsten Voss, PhD
                                    Associate Director, PreAnalytiX R&D, QIAGEN
                                    Biography

                                      Scientific Career:

                                      • Studied biology at University of Münster, Germany
                                      • Ph.D. in molecular genetics and microbiology
                                      • Postdoc at IBWF in Kaiserslautern, Germany

                                      Professional Career

                                      • Scientist at Artemis Pharmaceuticals Cologne
                                      • Since 2004 at QIAGEN
                                      • Associate Director R&D, PreAnalytiX
                                      • Developed PAXgene collection and nucleic acid isolation products
                                    Sponsored by

                                    For information on becoming a sponsor or exhibitor, please click here.


                                    C.E. Credits

                                    The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                                    Committee

                                    To download the Program Committee brochure here.


                                    • David Albala

                                      Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr ...

                                      See more See less
                                    • Antonio Baines

                                      Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a ...

                                      See more See less
                                    • Rajan Gupta

                                      Dr. Rajan T. Gupta, MD, is an Assistant Professor of Radiology in the Division of Abdominal Imaging at Duke University Medical Center, as well as the Director of the Abdominal Imaging Fellowship Program and a Faculty physician in the Duke Cancer Institute. Since 2009, he has been ...

                                      See more See less
                                    • Keith Knutson

                                      Keith L. Knutson, Ph.D., is a consultant in the Department of Immunology, Mayo Clinic in Florida, where he also serves as director of the Discovery and Translation Lab's Cancer Research Program. Dr. Knutson joined the staff of Mayo Clinic in 2005 and holds the academic rank of ...

                                      See more See less
                                    • Jonas Korlach

                                      Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He ...

                                      See more See less
                                    • Khyati Shah

                                      Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ...

                                      See more See less
                                    Help

                                    General LabRoots Questions

                                    email support@labroots.com  

                                    Virtual Events and Webinars

                                    Supported Configurations

                                    • Operating System Internet Explorer Firefox Chrome Safari
                                      Vista IE8+ FF10+ Chrome15+
                                      Windows 7 IE8+ FF10+ Chrome15+
                                      Windows 8 IE10 FF10+ Chrome15+
                                      Mac OS X   FF10+ Chrome15+ Safari5.1+
                                    • Cookie settings: session cookies enabled
                                    • Browser configuration must have JavaScript enabled
                                    • Adobe Flash player 10.2 or later

                                    To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                    Internet Connection

                                    • A minimum of 100Kbps is recommended for audio-only events
                                    • A minimum of 300Kbps is recommended for speaker on-video events

                                    Computer Equipment

                                    • Screen Resolution: Minimum 1024x768
                                    • Video Card: 65,000 colors minimum
                                    • Sound card and speakers (or headphones) for hearing webcast in full format
                                    • Audio Card: 16-bit minimum
                                    • RAM: 512MB of free RAM

                                    Firewall Protocol

                                    • HTTP on port 80 or HTTPS on port 443
                                    • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                    • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                    Work-At-Home Attendees

                                    • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                    For A Seamless Experience

                                    When using a mobile device, FREE Mobile Apps are available:

                                    - For viewing Webinars:

                                    - For viewing Virtual Events

                                    Attendee Guide

                                    • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                    Virtual Event and Webinar Support:

                                    Continuing Education (CME/CE) Support

                                    Show Resources
                                    Event Countdown
                                    • 0 Days
                                    • 0 Hours
                                    • 0 Minutes
                                    • 0 Seconds
                                    Attendees
                                    • See more